Dmk Pharmaceuticals Corp (DMKPQ)

$0.00 0.00 (N/A)
Market Cap 1,000.00
Revenue (ttm) 4.76M
Net Income (ttm) -26.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -556.30%
Debt to Equity Ratio 0.00
Volume 80,800
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 10.10M
Stochastic %K N/A
Beta 0.86
Analysts Strong Buy
Price Target $1.50

Company Profile

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, dru...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 858 997 2400
Address:
11682 El Camino Real, Suite 300, San Diego, United States
peanutscream
peanutscream Aug. 10 at 6:49 AM
$DMKPQ Please, correct me if I am wrong. I deepened my research with the help of AI and checking the docs and realized that, very likely, is really over for us. Seems we should have initiated a DERIVATIVE LAWSUIT so we could have had a voice (a presence) in the liquidation case and so, not removed by the liquidation trustee and the judge. So, even if the judge will require Catalent and USworldmeds to pay the damages, these will go to creditors only and if the damages claimed will be humongous will be simbolically only and money will remain to those companies. What a fraud, what a disgusting system! I hope everyone in charge will get their karma. (FU) $TBLT Another chit case
0 · Reply
peanutscream
peanutscream Jul. 31 at 12:05 AM
$DMKPQ
0 · Reply
Breton2018
Breton2018 Jul. 6 at 11:39 PM
$DMKPQ
0 · Reply
peanutscream
peanutscream Jun. 8 at 1:00 PM
$DMKPQ If it's game over and we were wiped out, why our offline shares still not removed by brokers?
2 · Reply
peanutscream
peanutscream Jun. 3 at 6:25 PM
$DMKPQ When damages??? 😤😤
1 · Reply
peanutscream
peanutscream May. 19 at 7:47 PM
$DMKPQ New dockets
1 · Reply
peanutscream
peanutscream May. 13 at 2:48 PM
$DMKPQ After 19 may we could read something
0 · Reply
peanutscream
peanutscream Apr. 7 at 6:58 AM
$DMKPQ This is what I thought then and asked AI. Thanks AI: DMK Pharmaceuticals (formerly Adamis Pharmaceuticals) faced an operational and legal deadlock that made a quick pivot nearly impossible. They couldn't simply "walk away" earlier due to exclusive contractual obligations, lack of liquidity, and the technical complexity of pharmaceutical manufacturing. Here are the main reasons why they waited until the Chapter 11 filing to take legal action: 1. Contractual Constraints and "Lock-in" Exclusivity Agreements: DMK had exclusive commercialization deals with US WorldMeds (USWM) for key products like the Zimhi nasal spray. Unilaterally breaking these contracts would have exposed the company to massive penalties and immediate legal battles they couldn't afford. Long-term Contracts with Catalent: The supply agreement with Catalent for the Symjepi product dated back to 2015 and had been automatically extended, tying DMK to a single manufacturer for years.
3 · Reply
peanutscream
peanutscream Mar. 23 at 6:42 PM
$DMKPQ
1 · Reply
peanutscream
peanutscream Feb. 4 at 10:10 AM
$DMKPQ New Docket 646
0 · Reply
Latest News on DMKPQ
No data available.
peanutscream
peanutscream Aug. 10 at 6:49 AM
$DMKPQ Please, correct me if I am wrong. I deepened my research with the help of AI and checking the docs and realized that, very likely, is really over for us. Seems we should have initiated a DERIVATIVE LAWSUIT so we could have had a voice (a presence) in the liquidation case and so, not removed by the liquidation trustee and the judge. So, even if the judge will require Catalent and USworldmeds to pay the damages, these will go to creditors only and if the damages claimed will be humongous will be simbolically only and money will remain to those companies. What a fraud, what a disgusting system! I hope everyone in charge will get their karma. (FU) $TBLT Another chit case
0 · Reply
peanutscream
peanutscream Jul. 31 at 12:05 AM
$DMKPQ
0 · Reply
Breton2018
Breton2018 Jul. 6 at 11:39 PM
$DMKPQ
0 · Reply
peanutscream
peanutscream Jun. 8 at 1:00 PM
$DMKPQ If it's game over and we were wiped out, why our offline shares still not removed by brokers?
2 · Reply
peanutscream
peanutscream Jun. 3 at 6:25 PM
$DMKPQ When damages??? 😤😤
1 · Reply
peanutscream
peanutscream May. 19 at 7:47 PM
$DMKPQ New dockets
1 · Reply
peanutscream
peanutscream May. 13 at 2:48 PM
$DMKPQ After 19 may we could read something
0 · Reply
peanutscream
peanutscream Apr. 7 at 6:58 AM
$DMKPQ This is what I thought then and asked AI. Thanks AI: DMK Pharmaceuticals (formerly Adamis Pharmaceuticals) faced an operational and legal deadlock that made a quick pivot nearly impossible. They couldn't simply "walk away" earlier due to exclusive contractual obligations, lack of liquidity, and the technical complexity of pharmaceutical manufacturing. Here are the main reasons why they waited until the Chapter 11 filing to take legal action: 1. Contractual Constraints and "Lock-in" Exclusivity Agreements: DMK had exclusive commercialization deals with US WorldMeds (USWM) for key products like the Zimhi nasal spray. Unilaterally breaking these contracts would have exposed the company to massive penalties and immediate legal battles they couldn't afford. Long-term Contracts with Catalent: The supply agreement with Catalent for the Symjepi product dated back to 2015 and had been automatically extended, tying DMK to a single manufacturer for years.
3 · Reply
peanutscream
peanutscream Mar. 23 at 6:42 PM
$DMKPQ
1 · Reply
peanutscream
peanutscream Feb. 4 at 10:10 AM
$DMKPQ New Docket 646
0 · Reply
peanutscream
peanutscream Feb. 2 at 6:21 PM
$DMKPQ Transcript regarding Hearing Held 1/20/2026 RE: Rule 16 Conference. Remote electronic access to the transcript is restricted until 5/4/2026. The transcript may be viewed at the Bankruptcy Court Clerk's Office. For information about how to obtain a transcript, call the Clerk's Office or Contact the Court Reporter/Transcriber, Reliable, at Telephone number 302-654-8080. Filed by Reliable Companies . Notice of Intent to Request Redaction Deadline Due By 2/9/2026. https://cases.creditorinfo.com/dmk/documents/docket
0 · Reply
peanutscream
peanutscream Feb. 2 at 3:02 PM
$DMKPQ COME ON...
0 · Reply
peanutscream
peanutscream Feb. 1 at 8:41 AM
$TBLT $DMKPQ Next week?
0 · Reply
peanutscream
peanutscream Jan. 31 at 10:08 AM
$DMKPQ Unbelievable, after all these days, nothing. 🤦🏻
1 · Reply
peanutscream
peanutscream Jan. 30 at 3:36 PM
$DMKPQ
0 · Reply
Sutliff
Sutliff Jan. 26 at 10:23 PM
$DMKPQ did we win? lol
0 · Reply
afatrader
afatrader Jan. 17 at 6:29 AM
$DMKPQ Jan 20
0 · Reply
Stocktrader4554
Stocktrader4554 Dec. 15 at 6:19 PM
$POET Can someone please do a Wellness check on @Tdc1! Last year he was diagnosed with AIDS due to a mixture of horrible Trading strategies and unprotected sex with @Astroboy56!! Help!! SOS!!! $ADMP $DMKPQ
3 · Reply
zpapanian
zpapanian Dec. 5 at 3:12 PM
$DMKPQ is anyone know what we can do with this i have 47K shares of it?
1 · Reply
RBrown78
RBrown78 Dec. 4 at 9:28 PM
$DMKPQ Just incase anyone is interested. "FFF Enterprises is Offering ZIMHI® (naloxone HCl Injection), Manufactured by ZMI Pharma Inc. Now available exclusively through FFF Enterprises." This is not a publicly traded company, so we cannot see how much or little they are selling. All I know is they got Zimhi and Symjepi, and some of those "molecules" for pennies on the dollar. 100s of millions of our money was used to fund these products. And then they get sold for less than 3M. Just criminal, but amazing how the bashers called it for years and years. All crooks.
0 · Reply
peanutscream
peanutscream Nov. 11 at 7:02 PM
$DMKPQ
0 · Reply
peanutscream
peanutscream Nov. 11 at 6:40 PM
$DMKPQ I missed it 😱 Not Belgium plant but Indiana one, anyway a recurrent issue for ex Catalent... Let's win the lawsuits, come on! 🤞🤞🤞
3 · Reply